SecBot SecBot
8-K ·Filed Aug 17, 2026

PROF

Profound Medical Corp.
NEUTRAL
Impact 2/10
Horizonmonths Processed3mo ago SEC0001171843-26-005575
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor the next quarterly report for any signs of operational disruption or financial reporting quality under the new interim CFO. The transition appears smooth, so no near-term trading catalyst from this change alone.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.55
T+0 close · Aug 17, 2026 · via day close
Latest settled
+17.25%
T+60 · $7.68
Vs SPY
+20.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $6.55entry
  2. T+1 · 3mo ago +6.87%α +7.55% · $7.00
  3. T+5 · 3mo ago +3.82%α +5.01% · $6.80
  4. T+20 · 2mo ago −13.28%α −11.30% · $5.68
  5. T+60 · 7d ago +17.25%α +20.20% · $7.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical announced the resignation of CFO Rashed Dewan and the appointment of Corporate Controller Matthew Sobczyk as Interim CFO, effective August 14, 2026. The CFO departure is orderly with a transition consulting agreement, and the interim CFO is an internal promotion with deep company knowledge, making this a routine management change with no immediate financial impact on operations.

Key Facts

  • CFO Rashed Dewan resigned effective August 14, 2026.
  • Matthew Sobczyk, previously Corporate Controller, appointed Interim CFO effective same date.
  • Dewan will serve as a consultant from August 17 to November 25, 2026, receiving CAD 200/hour + continued vesting of 20,000 RSUs.
  • Dewan receives a $375,000 cash severance payment.
  • Sobczyk's annual base salary set at CAD 300,414.58 with a 15% target bonus.
  • No financial guidance, preliminary results, or revenue/earnings data were disclosed.

Financial Impact

CFO severance payment of $375,000; no impact on revenue, earnings, or operations disclosed.

Risk Factors

  • Extended CFO vacancy could signal deeper organizational issues if a permanent replacement is not named within months.
  • Loss of institutional knowledge if the consulting transition period is insufficient.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-005575
Exhibit: exh_991.htm0001171843-26-005575
Document: 0001171843-26-005575-index-headers.html0001171843-26-005575
Document: 0001171843-26-005575-index.html0001171843-26-005575
Document: 0001171843-26-005575.txt0001171843-26-005575

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026